Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
Healthcare
$0.80 -5.22%
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
52W Low $0.39High $3.87
Volume 0.23M
Average 1.15M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$18.71M
FY 2025 · Annual
Investing Cash Flow
-$7.03M
FY 2025 · Annual
Financing Cash Flow
$40.30M
FY 2025 · Annual
+196.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.33M) | (63.34M) | (33.97M) | (56.58M) | (29.67M) |
| Depreciation & Amortization | 497K | 548K | 822K | 1.03M | 900K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.6M | 15.78M | 19.01M | 16.03M | 11.8M |
| Change in Working Capital | (3.43M) | 509K | (2.14M) | (544K) | 6.96M |
| Accounts Receivables | 0 | 0 | 0 | (428K) | (1.61M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 543K | 163K | (595K) | 711K | (1.05M) |
| Other Working Capital | (3.97M) | 346K | (1.55M) | (827K) | 9.62M |
| Other Non-Cash Items | (43.58M) | (10K) | (34.96M) | 4.57M | (8.7M) |
| Operating Cash Flow | (32.25M) | (46.52M) | (51.24M) | (35.5M) | (18.71M) |
| Capital Expenditures | (506K) | (1.62M) | (1.23M) | (268K) | (88K) |
| Acquisitions (Net) | 0 | (851K) | 0 | 0 | 0 |
| Purchases of Investments | 0 | (73.82M) | (73.26M) | (58.72M) | (33.97M) |
| Sales of Investments | 0 | 3M | 104.35M | 77.55M | 26.75M |
| Other Investing Activities | 0 | 851K | 0 | 1.25M | 278K |
| Investing Cash Flow | (506K) | (72.44M) | 29.86M | 19.81M | (7.03M) |
| Debt Repayment | (2.85M) | 29.57M | 0 | (5M) | (20.72M) |
| Common Stock Issued | 73.65M | 317K | 395K | 18.63M | 61.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 26K | (886K) | (162K) | (47K) | (59K) |
| Financing Cash Flow | 77.15M | 29.01M | 233K | 13.59M | 40.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 44.4M | (89.95M) | (21.14M) | (2.1M) | 14.56M |
| Free Cash Flow | (32.75M) | (48.13M) | (52.47M) | (35.76M) | (18.8M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$29.7M
+ D&A$900.0K
+ Stock-Based Comp$11.8M
+ Deferred Tax$0
+ Working Capital$7.0M
- Other Non-Cash-$8.7M
= Operating Cash Flow-$18.7M
- Capex-$88.0K
= Free Cash Flow-$18.8M
Analysis
FY2025 free cash flow is -$18.8M. FCF conversion is 63.4% of net income. Operating cash flow was -$18.7M, with capex of -$88.0K. The largest bridge item is Stock-Based Comp at $11.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 |
Does RANI generate free cash flow?
Rani Therapeutics Holdings, Inc. (RANI) generated -$18.80M of free cash flow in fiscal 2025.
How much operating cash flow does RANI produce?
Operating cash flow was -$18.71M, before capital expenditures of $88,000.00.
Continue the stock analysis
Jump to another research area for this company.